Canaccord Genuity Maintains Buy on Niagen Bioscience, Lowers Price Target to $9
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Susan Anderson maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and lowers the price target from $10 to $9.
Canaccord Genuity analyst Susan Anderson maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and lowers the price target from $10 to $9.